EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Primary HSV-2 Infection in an Immunocompromised Patient Reveals High Diversity of Drug-Resistance Mutations in the Viral DNA Polymerase

Hanna Helena Schalkwijk iD, Sarah Gillemot iD, Emilie Frobert, Florence Morfin, Sophie Ducastelle, Anne Conrad, Pierre Fiten iD, Ghislain Opdenakker iD, Robert Snoeck, Graciela Andrei iD

Viruses · 2025

DOI: 10.3390/v17070962 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Viruses, 2025. Verfasst von Hanna Helena Schalkwijk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Structural and Translational Virology Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medica…. Hauptthemen laut MEDLINE: DNA-Directed DNA Polymerase, Drug Resistance, Viral, Herpes Simplex, Herpesvirus 2, Human. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sciensano.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herpes simplex virus 2 (HSV-2) remains a significant cause of morbidity and mortality in immunocompromised individuals, despite the availability of effective antivirals. Infections caused by drug-resistant isolates are an emerging concern among these patients. Understanding evolutionary aspects of HSV-2 resistance is crucial for designing improved therapeutic strategies. Here, we characterized 11 HSV-2 isolates recovered from various body sites of a single immunocompromised patient suffering from a primary HSV-2 infection unresponsive to acyclovir and foscarnet. The isolates were analyzed phenotypically and genotypically (Sanger sequencing of viral thymidine kinase and DNA polymerase genes). Viral clone isolations, deep sequencing, viral growth kinetics, and dual infection competition assays were performed retrospectively to assess viral heterogeneity and fitness. Sanger sequencing identified mixed populations of DNA polymerase mutant variants. Viral clones were plaque-purified and genotyped, revealing 17 DNA polymerase mutations (K533E, A606V, C625R, R628C, A724V, S725G, S729N, I731F, Q732R, M789T/K, Y823C, V842M, R847C, F923L, T934A, and R964H) associated with acyclovir and foscarnet resistance. Deep-sequencing of the DNA polymerase detected drug-resistant variants ranging between 1 and 95%, although the first two isolates had a wild-type DNA polymerase. Some mutants showed reduced fitness, evidenced by (i) the frequency of variants identified by deep-sequencing not correlating with the proportion of mutants found by plaque-purification, (ii) loss of the variants upon passaging in cell culture, or (iii) reduced frequencies in competition assays. This study reveals the rapid evolution of heterogeneous drug-resistant HSV-2 populations under antiviral therapy, highlighting the need for alternative treatment options and resistance surveillance, especially in severe infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Directed DNA PolymeraseDrug Resistance, ViralHerpes SimplexHerpesvirus 2, HumanImmunocompromised HostMutationViral ProteinsFemaleHumansAcyclovirAntiviral AgentsFoscarnetGenetic VariationGenotypeAdultExodeoxyribonucleases

Stichwörter der Autor:innen

drug resistanceherpes simplex virus 2viral fitnessviral heterogeneity

Substanzen

AcyclovirAntiviral AgentsDNA polymerase, SimplexvirusDNA-Directed DNA PolymeraseFoscarnetViral ProteinsExodeoxyribonucleases

Autor:innen und Institutionen

  • Molecular Structural and Translational Virology Research Group, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
  • Virpath Unit, CIRI, Inserm U1111, CNRS, UMR5308, ENS Lyon, Université Claude Bernard Lyon 1 and Virology Unit, Institut des Agents Infectieux, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69004 Lyon, France.
  • Hematology Clinical Unit, Groupement Hospitalier Sud, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.
  • Infectious and Tropical Diseases Unit, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69004 Lyon, France.
  • Laboratory of Immunobiology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.

ORCID-Profile: Hanna Helena Schalkwijk, Sarah Gillemot, Pierre Fiten, Ghislain Opdenakker, Graciela Andrei

Förderung

  • Sciensano

Zitieren

APA

Schalkwijk, H. H., Gillemot, S., Frobert, E., Morfin, F., Ducastelle, S., Conrad, A., Fiten, P., Opdenakker, G., Snoeck, R., & Andrei, G. (2025). Primary HSV-2 Infection in an Immunocompromised Patient Reveals High Diversity of Drug-Resistance Mutations in the Viral DNA Polymerase. Viruses. https://doi.org/10.3390/v17070962

Vancouver

Schalkwijk HH, Gillemot S, Frobert E, Morfin F, Ducastelle S, Conrad A, et al. Primary HSV-2 Infection in an Immunocompromised Patient Reveals High Diversity of Drug-Resistance Mutations in the Viral DNA Polymerase. Viruses. 2025. doi:10.3390/v17070962

BibTeX
@article{Schalkwijk2025,
  author = {Schalkwijk, Hanna Helena and Gillemot, Sarah and Frobert, Emilie and Morfin, Florence and Ducastelle, Sophie and Conrad, Anne and Fiten, Pierre and Opdenakker, Ghislain and Snoeck, Robert and Andrei, Graciela},
  title = {Primary HSV-2 Infection in an Immunocompromised Patient Reveals High Diversity of Drug-Resistance Mutations in the Viral DNA Polymerase},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17070962}
}
Kostenlos starten →